Clean Beauty Connect is the leading network driving innovation in beauty and personal care towards a cleaner, more transparent industry. This summit provides the platform for brands to collaborate with innovation leaders, uniting the industry in its sustainability mission.The market value of clean beauty is expected to grow by $20 billion dollars before 2027 and the onset of the pandemic has made health and safety paramount, with clean formulations becoming table stakes.However, safety of ingredients is no longer enough for the conscious consumer with 60% looking to buy from socially and environmentally responsible companies. In such a fast-evolving industry, it is imperative brands meet those demands to gain the competitive edge.We are the established platform bringing together brands and innovation leaders to share their expertise and allow you to meet your sustainability goals. Join this event to gain the knowledge and connections to ensure your company’s next step in becoming clean in 2021.
With an increasing number of projects entering the pipeline both clinically and pre-clinically aimed at targeting transcription factors that were previously thought to be “undruggable”, the industry is ready to develop further insight into the commercialization of TF-based therapeutics within cancer and other disease settings. With multiple strategies having entered the clinic from PPI inhibitors, modulators of TF expression, and the first PROTAC-based degraders, it could only be a matter of time before the first therapy enters the market.The inaugural Transcription Factor Drug Development Congress is the first of its kind anywhere in the world! We will bring together leading industry players within large pharma and biotech, along with expert academics in the oncology drug discovery space – providing an open forum to facilitate the sharing of in vitro and in vivo data, as well as build a deeper understanding of transcriptional machinery to make the ‘undruggable’ druggable.Expect to hear strategies to overcome the structural biology, pharmacology, and chemistry obstacles in the design and development of TF-based therapeutics by hearing real success stories in the targeting of transcription factors for therapeutic benefit.Develop further insight into targeting MYC, STAT, and other transcription factors with a role in disease.
Beauty Connect, is the leading digital summit connecting indie brands, multinationals, retailers and industry suppliers from across the US and beyond.The beauty world has shifted immensely but one thing hasn't changed, the need to secure partnerships. The big question is... how has the beauty landscape changed and how can you stand out and emerge as a leading brand in a new age of beauty?Building on the global success of the Beauty & Money Series, Beauty Connect will enable you to forge long-lasting and ever-present relationships with the customer. Brands that invest in customer engagement and experience can expect a 5.7 times increase in revenue.Take away the latest insights, opportunities, and connections you need to strengthen your company, and come out of 2020 thriving. Learn what the 'new normal' is, connect with industry-experts in over 20 private 1-2-1 meetings, and showcase your brand in our exclusive Beauty & Money Spotlight Award.You’re never too big to fail, you’re never too small to thrive – Beauty Connect USA is the virtual event for forging partnerships, acquiring the latest marketing intelligence and building a brand strategy that will ensure your relevancy and success.A digital event will be a first for many...Embracing the challenges of live events in these current times, brings new opportunity to connect online.Taking place across 3 mornings that work for both PDT and EDT timezones, Beauty Connect promises to deliver the same high quality content sessions but with many more interactive elements including; panel discussions, polls, live Q&A and video conferencing networking opportunities - all from the comfort of your own home.
Most enzymes found in nature are not suitable for industrial purposes. The field of protein and enzyme engineering is growing at a rapid rate, with competition within industries high and the need to optimise performance greater than ever. The global enzymes market size was valued at $9.9 billion in 2019 and is expected to grow at a compound annual growth rate (CAGR) of 7.1% from 2020 to 2027.With pharmaceutical, flavour & fragrance, consumer goods, animal feed, and agrochemical sectors all approaching the design, build and generation of new biocatalysts and molecules not found in nature, come and learn from our line-up of leading speakers to get an update on the new technologies used in the field of strain and protein engineering.The 2nd Annual European Protein Engineering Congress, dedicated to uncovering the new and emerging practices, techniques and methods of protein and enzyme engineering across industries, will return 24th-25th November and 1st December 2020. What’s new for 2020?On 24th-25th November, we will once again deliver case studies from the industry along with content on directed evolution, novel API development, AI & machine learning, and computational approaches for enzyme discovery.What’s happening 1st December?This year’s Protein Engineering Congress will be delivered virtually. Therefore we will be making all content shown on 24th-25th November on-demand, allowing you time to dissolve and digest the content ready for the third day on 1st December, which will deliver in-depth discussions on industry challenges, dedicated time for networking and 1-2-1 meetings, exclusive roundtable discussion with industry leaders, and exciting partnership announcements from within the field.Attend and you'll be able to; increase your product pipeline, increase product efficiency and increase differentiation by meeting the experts in the biocatalysis and protein engineering space.This is not your average protein engineering congress...it's about industry, sharing knowledge and optimising your protein engineering method for the best outcomes.
Onco Cell Therapy Summit (OCTS), formerly the CAR-T Congress, is an event that brings industry together to share novel research, manufacturing techniques and regulatory best practice. Each session of OCTS 2020 is dedicated to translating your novel data assets & IP into commercially viable oncological therapies.OCTS is a 4-track event and whilst bringing together the key decision makers for CAR-T therapies, this year’s event will have an added focus on the ground breaking science that is driving the surge of interest in harnessing alternative cell therapies in cancer treatments.With 2 of our tracks comprised of research on CAR-T and alternative cell therapies, the other pillar in rolling out these therapies is increasing the affordability of the treatments. The other two tracks will delve into best practice in commercialization and manufacturing of immuno-oncological cell therapies.Each day of the summit will conclude in plenary room panels that spin out into bespoke roundtable discussions to break down the key challenges in major topics to R&D, manufacturing and commercialization.
Senior Living Transformation Technology Leaders Summit
22-31 Mar 2021
Virtual Summit
In the past many senior care and housing providers have not had the risk appetite to drive digital transformation and adopt new technologies within their business. The pandemic has forced the hand of many risk adverse boards and executives to see the business-critical role technology, and the data it generates can play in facing this monumental disruption to normal operating models.Now is the time for senior care executives to take a step back, assess what technology is right for their current and future business needs and build a strategic roadmap for how to get there.The Senior Living Transformation:Technology Leaders virtual series will provide you with practical workshops, interactive roundtables and executive panels. Each individual session has been designed in response to feedback from the leaders in the senior care industry.This March we will be tackling how to:Determine the right connectivity and infrastructure required to adapt to the ‘new normal’Implement and maximize resident experience technologyLeverage sales and marketing technology & lead digital transformationBuild and execute an IT roadmap and strategyPilot and implement a successful innovation and technology pilot program This series is perfect for executives ready to build and execute a strategic IT roadmap at their organization and who are determining the priority areas for their budget.
2019 was a pivotal year for the skin microbiome, with multinational conglomerates moving into the space, recognizing the commercial value of skin microbiome-based products as the next step in a consumer’s skincare regime but the innovation doesn’t end there…This year is all about the major advancements of sequencing and analysis in this space, and how we can use data to inform product development. 2020 is all about the relationship between skin microbiome based-products, skin conditions, personalization, skin-gut supplements, and anti-aging. Building on the hugely successful global Skin Microbiome series which brought together over 600 industry leaders from Pharmaceutical, Beauty and Personal Care, Independent Skincare Brands, Bio-techs, Researchers and Academics, Kisaco Research presents Microbiome Connect: Skin USA, an all-encompassing event, which runs alongside Microbiome Connect: Human USA as a virtual event, June 3 - 5.What’s different?This year, you can expect 5 unique topics, more attendees and more networking opportunities to explore:Ground-breaking research into how best treat these skin diseases and develop treatments targeting acne vulgaris, atopic dermatitis, psoriasis Vulgaris and rosacea.The translation and commercialization of product claims, the latest trends and protecting your intellectual property.The convergence between the skin-gut axis and the supplement market.Personalized formulation and product developmentTools to increase product claims using sequencing and bioinformatics.Join key opinion leaders and expert speakers across three days to translate the latest skin microbiome data and market analysis into truly commercial and competitive beauty and personal care products.Skin microbiome based-products have been disrupting the beauty industry for the past two years, the question is, how can you differentiate your products?
Shareholders, employees, customers and a wide range of stakeholders require corporates to show a tangible, impactful commitment to renewable energy. As global energy usage and needs are re-defined by these groups, corporates are increasingly focused on reducing their environmental footprint and securing lower energy costs. Corporate PPAs enable companies to achieve their carbon emission reduction goals and are gaining momentum globally.What’s on everybody’s mind now is the impact of Covid-19 on power prices and on existing and future contracts. What is happening with corporate green agendas and demand, what state bail-out/support packages are available in Europe and how are buyers, generators and investors responding?This brings us to launch Corporate renewables 2020 Virtual Summit. The size and frequency of deals have increased quickly in recent years to more complex and innovative buyer consortia, VFA and proxy swap agreements. However, in Europe the business model for PPAs is yet to reach its potential. The total volume of corporate renewable PPAs signed in Europe in 2018 amassed to 1.9 GW while in the States it reached 8.5 GW.You’ll delve deep into European inter-connectedness and regulation, risk mitigation and creating strong partnerships between the procurer and generator. You’ll also analyse emerging contracts and the financial and operational benefits they offer corporates. The collegial discussion promotes transparent free flowing discussions in an informal setting and under strict Chatham House Rules.
The targeted protein degradation field is expanding, gone are the days of simple proof of concept…. We now have LYTACs, AUTACs and ATTECs as well as numerous PROTAC and Molecular Glue companies with millions of dollars worth of investment. C4 netted $182.4 million in IPO, and Nurix and Kymera closed funding with $120 million and $102 million apiece. With several start-ups launching, including Lycia and Amphista therapeutics, investment in this area is booming, and it’s not slowing down.There are currently over 85 degraders being considered at various stages of development, both preclinical and clinical, as well as in discovery. However, key questions are yet to be answered:How will degrader research translate in the clinic?Why are we still struggling with oral bioavailability?How can we effectively validate novel targets and degrade ‘undruggable’ targets of interest?What can be learned from the new, emerging degrader strategies that are emerging?Once again bringing together leaders from pharma, biotech and academia as well as innovative service providers, the North American Protein Degradation Congress is back to give you the full picture from molecular biology right the way up to the latest in medicinal chemistry and clinical data.Learn to create clinically applicable degraders to the entire proteome at the digital North American Protein Degradation Congress 2021.
150+ industry executives, from strategic buyers, financial buyers and independent pet brands, all looking for their next investment, acquisition or business partnering opportunity.
